Xueyan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xueyan Wang has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Na Xi
Department of Medical Genetics and Prenatal Diagnosis Sichuan Provincial Women's and Children's Hospital/The Affiliated Women's and Children's Hospital of Chengdu Medical College Chengdu Sichuan China
7 shared publicationsShengfang Qin
Department of Medical Genetics and Prenatal Diagnosis, Sichuan Provincial Women's and Children's Hospital, The Affiliated Women's and Children's Hospital of Chengdu Medical College
5 shared publicationsJin Wang
Department of Medical Genetics and Prenatal Diagnosis Sichuan Provincial Women's and Children's Hospital/The Affiliated Women's and Children's Hospital of Chengdu Medical College Chengdu Sichuan China
4 shared publicationsJing Zhao
Center for Medical Genetics and Prenatal Diagnosis, Xueyan Wang, Center for Medical Genetics and Prenatal Diagnosis, Sichuan Provincial Women’s and Children’s Hospital, The Affiliated Women’s and Children’s Hospital of Chengdu Medical College, Chengdu, Sichuan 610045, China
4 shared publicationsMengjia Yan
Department of Medical Genetics and Prenatal Diagnosis Sichuan Provincial Women's and Children's Hospital/The Affiliated Women's and Children's Hospital of Chengdu Medical College Chengdu Sichuan China
4 shared publications- Shengfang Qin
Department of Medical Genetics and Prenatal Diagnosis Sichuan Provincial Women's and Children's Hospital/The Affiliated Women's and Children's Hospital of Chengdu Medical College Chengdu Sichuan China
4 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (11) , 1732-1745
Structural Variation Sequencing of 26 Amniotic Fluid Samples With Partial Gene Duplications and Postnatal Follow‐Up of the Fetuses
Objectives: Partial gene duplications (PGDups) are a significant contributor to genetic disease. The precise genomic location and structure of PGDups are often unresolved using conventional methods, so prenatal diagnosis for PGDups is challenging, especially without ultrasound abnormalities. Methods: We retrospectively applied structural variation sequencing (SVseq) to 26 amniotic fluid samples with PGDups initially identified by chromosomal microarray or sequencing. SVseq utilized mate‐pair library construction and high‐throughput sequencing to map PGDup structures. Pathogenicity was classified using ACMG guidelines, followed by postnatal phenotypic follow‐up. Results: SVseq deciphered the PGDup structure for all twenty‐six cases. Twenty‐two (84.62%) were tandem duplications (TDs), three (11.54%) chromosomal complex rearrangements (CCRs), and one (3.85%) had no duplication. Among twenty‐two TDs, thirteen were extragenic (TDEG), preserving gene integrity, and were classified as benign or variants of uncertain significance (VUS). Nine were intragenic (TDIG), disrupting gene structure, and were rated pathogenic or likely pathogenic (P/LP) or VUS. Postnatal follow‐up revealed obvious abnormal phenotypes in only two TDIG cases (one inherited and one de novo). Conclusion: SVseq effectively resolves PGDup location and structure, allowing confident pathogenicity assessment and clear genotype‐phenotype correlation. SVseq is a robust method for prenatal PGDup evaluation that could be adopted in diagnostic protocols to improve clinical outcomes.
- 29 June 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (11) , 1732-1745
Open AccessStructural Variation Sequencing of 26 Amniotic Fluid Samples With Partial Gene Duplications and Postnatal Follow‐Up of the Fetuses
Objectives: Partial gene duplications (PGDups) are a significant contributor to genetic disease. The precise genomic location and structure of PGDups are often unresolved using conventional methods, so prenatal diagnosis for PGDups is challenging, especially without ultrasound abnormalities. Methods: We retrospectively applied structural variation sequencing (SVseq) to 26 amniotic fluid samples with PGDups initially identified by chromosomal microarray or sequencing. SVseq utilized mate‐pair library construction and high‐throughput sequencing to map PGDup structures. Pathogenicity was classified using ACMG guidelines, followed by postnatal phenotypic follow‐up. Results: SVseq deciphered the PGDup structure for all twenty‐six cases. Twenty‐two (84.62%) were tandem duplications (TDs), three (11.54%) chromosomal complex rearrangements (CCRs), and one (3.85%) had no duplication. Among twenty‐two TDs, thirteen were extragenic (TDEG), preserving gene integrity, and were classified as benign or variants of uncertain significance (VUS). Nine were intragenic (TDIG), disrupting gene structure, and were rated pathogenic or likely pathogenic (P/LP) or VUS. Postnatal follow‐up revealed obvious abnormal phenotypes in only two TDIG cases (one inherited and one de novo). Conclusion: SVseq effectively resolves PGDup location and structure, allowing confident pathogenicity assessment and clear genotype‐phenotype correlation. SVseq is a robust method for prenatal PGDup evaluation that could be adopted in diagnostic protocols to improve clinical outcomes.
- Open Access
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1799731
Correcting PVS1 overestimation: clinical insights into rescue transcripts and variant reclassification in 4 prenatal cases
Background: As NGS has become more widely used in the diagnosis of rare diseases, an increasing number of variants of uncertain significance (VUS) have been detected, and their interpretation remains challenging. In particular,when a LOF variant in a non-conserved exon of the MANE transcript is detected by ES, yet the individual carrying this variant exhibits no clinical manifestations. In this context, the ACMG Splicing Subgroup introduced the term 'rescue transcripts' to guide the interpretation of LOF variants located within non-conserved exons. Methods: In this study, the properties of four different variants were characterised using in silico predictions, protein structural analysis, population frequency data, and clinical observations. Results: Three variants ( AMMECR1 :c.220C>T; GLI2 :c.162_163delCT; COL11A1 :c.1245+1G>A) were reclassified as likely benign (LB)/VUS because rescue transcripts were identified in the corresponding genes. Another variant ( EHMT1 :exon2-10 del) was reclassified as a VUS, as exons 2-10 may represent non-constitutive exons, and the deletion (p.8A–549E del) may not affect protein function. Therefore, this variant should not be assigned a PVS1 code. Conclusion: The presented case studies provide actionable recommendations for identifying rescue transcripts and enhance the understanding of the correct application of PVS1 codes.
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1799731
Open AccessCorrecting PVS1 overestimation: clinical insights into rescue transcripts and variant reclassification in 4 prenatal cases
Background: As NGS has become more widely used in the diagnosis of rare diseases, an increasing number of variants of uncertain significance (VUS) have been detected, and their interpretation remains challenging. In particular,when a LOF variant in a non-conserved exon of the MANE transcript is detected by ES, yet the individual carrying this variant exhibits no clinical manifestations. In this context, the ACMG Splicing Subgroup introduced the term 'rescue transcripts' to guide the interpretation of LOF variants located within non-conserved exons. Methods: In this study, the properties of four different variants were characterised using in silico predictions, protein structural analysis, population frequency data, and clinical observations. Results: Three variants ( AMMECR1 :c.220C>T; GLI2 :c.162_163delCT; COL11A1 :c.1245+1G>A) were reclassified as likely benign (LB)/VUS because rescue transcripts were identified in the corresponding genes. Another variant ( EHMT1 :exon2-10 del) was reclassified as a VUS, as exons 2-10 may represent non-constitutive exons, and the deletion (p.8A–549E del) may not affect protein function. Therefore, this variant should not be assigned a PVS1 code. Conclusion: The presented case studies provide actionable recommendations for identifying rescue transcripts and enhance the understanding of the correct application of PVS1 codes.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Genetic Analysis and Reproductive Intervention in a Duchenne Muscular Dystrophy Family With Cryptic Complex Chromosomal Rearrangement Identified by Structural Variation Sequencing
Duchenne/Becker muscular dystrophy (DMD/BMD) is caused by variants in the X‐linked DMD gene—most commonly deletions, duplications, or point mutations, and only rarely by complex chromosomal rearrangements (CCRs). In this study, structural variant sequencing (SVseq) was applied to a 14‐year‐old male patient with DMD. Although the patient exhibited typical symptoms, conventional tests—including karyotype analysis, gene panel, whole‐exome sequencing (WES), and multiplex ligation–dependent probe amplification (MLPA)—were all negative. SVseq identified a novel complex rearrangement on the X chromosome, comprising a 974,456 bp inversion spanning the 5 ′ UTR and Exons 1–2 of the DMD gene, flanked by two microdeletions of 7285 and 6468 bp (NC_000023.11:g.[32865334_32872619del;32872619_33847075inv33847075_33853543del]). This rearrangement disrupts the DMD coding sequence and is classified as a pathogenic variant. Short tandem repeat (STR) analysis confirmed the familial relationship, whereas PCR and Sanger sequencing precisely mapped the breakpoints, establishing that the mutation arose de novo in his mother and was maternally inherited. Reproductive interventions—including preimplantation genetic testing for monogenic disorders (PGT‐M) and second‐trimester prenatal diagnosis—enabled the successful birth of a healthy male child. SVseq demonstrated clear advantages over standard methods for detecting CCRs, highlighting its value in genetically elusive cases. We recommend SVseq as a complementary diagnostic tool for unresolved DMD cases where conventional testing does not explain the findings. This approach can enhance diagnostic yield and support informed family planning.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessGenetic Analysis and Reproductive Intervention in a Duchenne Muscular Dystrophy Family With Cryptic Complex Chromosomal Rearrangement Identified by Structural Variation Sequencing
Duchenne/Becker muscular dystrophy (DMD/BMD) is caused by variants in the X‐linked DMD gene—most commonly deletions, duplications, or point mutations, and only rarely by complex chromosomal rearrangements (CCRs). In this study, structural variant sequencing (SVseq) was applied to a 14‐year‐old male patient with DMD. Although the patient exhibited typical symptoms, conventional tests—including karyotype analysis, gene panel, whole‐exome sequencing (WES), and multiplex ligation–dependent probe amplification (MLPA)—were all negative. SVseq identified a novel complex rearrangement on the X chromosome, comprising a 974,456 bp inversion spanning the 5 ′ UTR and Exons 1–2 of the DMD gene, flanked by two microdeletions of 7285 and 6468 bp (NC_000023.11:g.[32865334_32872619del;32872619_33847075inv33847075_33853543del]). This rearrangement disrupts the DMD coding sequence and is classified as a pathogenic variant. Short tandem repeat (STR) analysis confirmed the familial relationship, whereas PCR and Sanger sequencing precisely mapped the breakpoints, establishing that the mutation arose de novo in his mother and was maternally inherited. Reproductive interventions—including preimplantation genetic testing for monogenic disorders (PGT‐M) and second‐trimester prenatal diagnosis—enabled the successful birth of a healthy male child. SVseq demonstrated clear advantages over standard methods for detecting CCRs, highlighting its value in genetically elusive cases. We recommend SVseq as a complementary diagnostic tool for unresolved DMD cases where conventional testing does not explain the findings. This approach can enhance diagnostic yield and support informed family planning.
- Open Access
- 4 July 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (12) , 1525-1538
A Prospective Evaluation of the Diagnostic Utility for Low‐Coverage Genome Sequencing in Prenatal Samples: A Comparison With Chromosomal Microarray Analysis
Objective: The present study aimed to evaluate the efficacy of LC‐GS in detecting clinically relevant chromosomal abnormalities in comparison with conventional CMA within a prenatal context. Methods: We conducted a prospective study involving 200 amniotic fluid samples. All specimens were analyzed via LC‐GS and traditional tests, including CMA and karyotyping. LC‐GS was performed with 3X coverage to gauge its proficiency in identifying copy number variations (CNVs), aneuploidies, regions of homozygosity (ROH), and chromosome mosaicism. Data from both methods were compared to evaluate their sensitivity, specificity, and overall clinical utility. Results: LC‐GS at a depth of 3X identified a total of 77 positive samples, yielding a detection rate of 38.5% (77/200). This included 17 cases of aneuploidy, 36 instances of CNVs, 20 cases linked to ROH, and 8 cases of chromosomal mosaicism. LC‐GS demonstrated high concordance with CMA in aneuploidy, CNVs, ROH, and chromosomal mosaicism, achieving a diagnostic yield of 21% (42/200), with additional benefits of reduced cost. Moreover, LC‐GS outperformed CMA in terms of resolution for identifying submicroscopic CNVs. Conclusion: LC‐GS presents a robust alternative to CMA for prenatal diagnosis, effectively identifying aneuploidies, CNVs, chromosomal mosaicism, and ROH. It delivers comparable sensitivity and specificity in the detection of a wide spectrum of genomic abnormalities.
- 4 July 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (12) , 1525-1538
Open AccessA Prospective Evaluation of the Diagnostic Utility for Low‐Coverage Genome Sequencing in Prenatal Samples: A Comparison With Chromosomal Microarray Analysis
Objective: The present study aimed to evaluate the efficacy of LC‐GS in detecting clinically relevant chromosomal abnormalities in comparison with conventional CMA within a prenatal context. Methods: We conducted a prospective study involving 200 amniotic fluid samples. All specimens were analyzed via LC‐GS and traditional tests, including CMA and karyotyping. LC‐GS was performed with 3X coverage to gauge its proficiency in identifying copy number variations (CNVs), aneuploidies, regions of homozygosity (ROH), and chromosome mosaicism. Data from both methods were compared to evaluate their sensitivity, specificity, and overall clinical utility. Results: LC‐GS at a depth of 3X identified a total of 77 positive samples, yielding a detection rate of 38.5% (77/200). This included 17 cases of aneuploidy, 36 instances of CNVs, 20 cases linked to ROH, and 8 cases of chromosomal mosaicism. LC‐GS demonstrated high concordance with CMA in aneuploidy, CNVs, ROH, and chromosomal mosaicism, achieving a diagnostic yield of 21% (42/200), with additional benefits of reduced cost. Moreover, LC‐GS outperformed CMA in terms of resolution for identifying submicroscopic CNVs. Conclusion: LC‐GS presents a robust alternative to CMA for prenatal diagnosis, effectively identifying aneuploidies, CNVs, chromosomal mosaicism, and ROH. It delivers comparable sensitivity and specificity in the detection of a wide spectrum of genomic abnormalities.
- Open Access
- 20 March 2025
- Published by Wolters Kluwer Health in Maternal-Fetal Medicine
- Vol. 7 (2) , 109-111
EBF3 Gene-Related Fetal Phenotypes
- 20 March 2025
- Published by Wolters Kluwer Health in Maternal-Fetal Medicine
- Vol. 7 (2) , 109-111
Open AccessEBF3 Gene-Related Fetal Phenotypes
- Open Access
- 22 November 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (11) , e70029
Long‐Read Sequencing Identifying the Genetic Complexity of Congenital Adrenal Hyperplasia in the Pedigree
Background: High sequence homology between CYP21A2 and CYP21A1P poses challenges to genetic diagnosis of congenital adrenal hyperplasia (CAH) due to 21‐hydroxylase deficiency (21‐OHD). Traditional genetic testing is unable to provide an accurate diagnosis due to the genetic complexity of CAH.Methods: Deletions, duplications, and recombination breakpoints were precisely identified by long‐read sequencing (LRS).Results: This study presented a pregnant woman, a 21‐OHD carrier detected by MLPA, and her husband, a normal subject also detected by MLPA. The fetus was suspected of having 21‐OHD based on clinical presentations such as enlarged adrenal glands, atypical external genitalia and karyotyping of 46, XX. LRS further identified the fetus as having the most severe salt‐wasting (SW) form of 21‐OHD with a compound heterozygote genotype. One allele was TNXA/TNXB CH‐2, while the other allele was CYP21A1P/CYP21A2 CH‐8. LRS precisely determined the genotypes of the fetus's father and grandmother with duplications, which misdiagnosed by MLPA. The multidisciplinary team recommended immediate glucocorticoid and mineralocorticoid treatment for the child after birth to prevent life‐threatening adrenal crisis.Conclusions: LRS provides precise diagnosis for family members with CYP21A2 deletion or duplication, improving disease management and preventing potential adrenal crises. When used in pre‐pregnancy genetic testing, LRS can indicate high genetic risk and guide the appropriate therapy during pregnancy and immediately after birth.
- 22 November 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (11) , e70029
Open AccessLong‐Read Sequencing Identifying the Genetic Complexity of Congenital Adrenal Hyperplasia in the Pedigree
Background: High sequence homology between CYP21A2 and CYP21A1P poses challenges to genetic diagnosis of congenital adrenal hyperplasia (CAH) due to 21‐hydroxylase deficiency (21‐OHD). Traditional genetic testing is unable to provide an accurate diagnosis due to the genetic complexity of CAH.Methods: Deletions, duplications, and recombination breakpoints were precisely identified by long‐read sequencing (LRS).Results: This study presented a pregnant woman, a 21‐OHD carrier detected by MLPA, and her husband, a normal subject also detected by MLPA. The fetus was suspected of having 21‐OHD based on clinical presentations such as enlarged adrenal glands, atypical external genitalia and karyotyping of 46, XX. LRS further identified the fetus as having the most severe salt‐wasting (SW) form of 21‐OHD with a compound heterozygote genotype. One allele was TNXA/TNXB CH‐2, while the other allele was CYP21A1P/CYP21A2 CH‐8. LRS precisely determined the genotypes of the fetus's father and grandmother with duplications, which misdiagnosed by MLPA. The multidisciplinary team recommended immediate glucocorticoid and mineralocorticoid treatment for the child after birth to prevent life‐threatening adrenal crisis.Conclusions: LRS provides precise diagnosis for family members with CYP21A2 deletion or duplication, improving disease management and preventing potential adrenal crises. When used in pre‐pregnancy genetic testing, LRS can indicate high genetic risk and guide the appropriate therapy during pregnancy and immediately after birth.
- Open Access
- 16 September 2024
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 52 (9)
Performance evaluation of noninvasive prenatal testing on 24 chromosomes in a cohort of 118,969 pregnant women in Sichuan, China
Objective: This study aimed to comprehensively analyze the detection capacity of non-invasive prenatal testing (NIPT) for chromosomal abnormalities of all 24 chromosomes, as well as high-risk indications for pregnancy and the fetal fraction, in a large cohort. Methods: We retrospectively enrolled 118,969 pregnant women who underwent NIPT at Sichuan Provincial Maternity and Child Health Care Hospital from March 2019 to June 2022. The sensitivity, specificity, positive predictive value, negative predictive value, and positive chromosomal abnormality rate were calculated. The fetal fraction based on gestational age, maternal body mass index, and number was examined. Results: NIPT demonstrated > 99% sensitivity and specificity for almost all of the common trisomies (T21, T18, and T13), sex chromosomal aneuploidies, rare autosomal trisomies, and microdeletion/microduplication syndromes. Positive predictive values varied from 12.0% to 89.6%. Advanced maternal age was associated with an increased risk of three major aneuploidies. The fetal fraction was positively correlated with gestational age and negatively correlated with the maternal body mass index. Conclusions: NIPT can be used to effectively screen for chromosomal abnormalities across all 24 chromosomes. Advanced maternal age is a risk factor for high-risk pregnancy, and careful consideration of the fetal fraction is essential during NIPT.
- 16 September 2024
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 52 (9)
Open AccessPerformance evaluation of noninvasive prenatal testing on 24 chromosomes in a cohort of 118,969 pregnant women in Sichuan, China
Objective: This study aimed to comprehensively analyze the detection capacity of non-invasive prenatal testing (NIPT) for chromosomal abnormalities of all 24 chromosomes, as well as high-risk indications for pregnancy and the fetal fraction, in a large cohort. Methods: We retrospectively enrolled 118,969 pregnant women who underwent NIPT at Sichuan Provincial Maternity and Child Health Care Hospital from March 2019 to June 2022. The sensitivity, specificity, positive predictive value, negative predictive value, and positive chromosomal abnormality rate were calculated. The fetal fraction based on gestational age, maternal body mass index, and number was examined. Results: NIPT demonstrated > 99% sensitivity and specificity for almost all of the common trisomies (T21, T18, and T13), sex chromosomal aneuploidies, rare autosomal trisomies, and microdeletion/microduplication syndromes. Positive predictive values varied from 12.0% to 89.6%. Advanced maternal age was associated with an increased risk of three major aneuploidies. The fetal fraction was positively correlated with gestational age and negatively correlated with the maternal body mass index. Conclusions: NIPT can be used to effectively screen for chromosomal abnormalities across all 24 chromosomes. Advanced maternal age is a risk factor for high-risk pregnancy, and careful consideration of the fetal fraction is essential during NIPT.
- Open Access
- 29 December 2022
- Published by Wiley in Genetics Research
- Vol. 2022, 1-7
Assessment of Combined Karyotype Analysis and Chromosome Microarray Analysis in Prenatal Diagnosis: A Cohort Study of 3710 Pregnancies
Objective. The current study aimed to compare the characteristics of chromosome abnormalities detected by conventional G-banding karyotyping, chromosome microarray analysis (CMA), or fluorescence in situ hybridization (FISH)/CNVplex analysis and further explore the application value of combined karyotype analysis and CMA in prenatal diagnosis with a larger sample size. Methods. From March 2019 to March 2021, 3710 amniocentesis samples were retrospectively collected from women who accepted prenatal diagnosis at 16 to 22+6 weeks of pregnancy. The pregnant women underwent karyotype analysis and CMA. In the case of fetal chromosomal mosaicism, FISH or CNVplex analysis was utilized for validation. Results. In total, 3710 G-banding karyotype results and CMA results from invasive prenatal diagnosis were collected. Of these, 201 (5.41) fetuses with an abnormal karyotype were observed. The CMA analysis showed that the abnormality rate was 9.14 (340/3710). The detection rate of CMA combined with karyotype analysis was 0.35 higher than that of CMA alone and 4.08 higher than that of karyotyping alone. Additionally, 12 cases had abnormal karyotype analysis, despite normal CMA results. To further detect the chromosome mosaicism, we used FISH analysis to correct the karyotype results of case 1. Correspondingly, a total of 157 cases showed abnormal CMA results but normal karyotype analysis. We also found chromosomal mosaicism in 4 cases using CMA. Moreover, CNVplex and CMA demonstrated that representative case 15 was mosaicism for trisomy 2. Conclusions. Conventional G-banding karyotyping and CMA have their own advantages and limitations. A combination of karyotype analysis and CMA can increase the detection rate of chromosome abnormalities and make up for the limitation of signal detection.
- 29 December 2022
- Published by Wiley in Genetics Research
- Vol. 2022, 1-7
Open AccessAssessment of Combined Karyotype Analysis and Chromosome Microarray Analysis in Prenatal Diagnosis: A Cohort Study of 3710 Pregnancies
Objective. The current study aimed to compare the characteristics of chromosome abnormalities detected by conventional G-banding karyotyping, chromosome microarray analysis (CMA), or fluorescence in situ hybridization (FISH)/CNVplex analysis and further explore the application value of combined karyotype analysis and CMA in prenatal diagnosis with a larger sample size. Methods. From March 2019 to March 2021, 3710 amniocentesis samples were retrospectively collected from women who accepted prenatal diagnosis at 16 to 22+6 weeks of pregnancy. The pregnant women underwent karyotype analysis and CMA. In the case of fetal chromosomal mosaicism, FISH or CNVplex analysis was utilized for validation. Results. In total, 3710 G-banding karyotype results and CMA results from invasive prenatal diagnosis were collected. Of these, 201 (5.41) fetuses with an abnormal karyotype were observed. The CMA analysis showed that the abnormality rate was 9.14 (340/3710). The detection rate of CMA combined with karyotype analysis was 0.35 higher than that of CMA alone and 4.08 higher than that of karyotyping alone. Additionally, 12 cases had abnormal karyotype analysis, despite normal CMA results. To further detect the chromosome mosaicism, we used FISH analysis to correct the karyotype results of case 1. Correspondingly, a total of 157 cases showed abnormal CMA results but normal karyotype analysis. We also found chromosomal mosaicism in 4 cases using CMA. Moreover, CNVplex and CMA demonstrated that representative case 15 was mosaicism for trisomy 2. Conclusions. Conventional G-banding karyotyping and CMA have their own advantages and limitations. A combination of karyotype analysis and CMA can increase the detection rate of chromosome abnormalities and make up for the limitation of signal detection.
- 10 July 2020
- Vol. 37 (7) , 771-773
[Prenatal diagnosis of a case of Pallister-Killian syndrome].
To carry out G-banded chromosomal karyotyping and chromosomal microarray analysis (CMA) for a fetus featuring multiple malformations. The fetus was found to have increased nuchal thickness, generalized edema, asymmetric lower limbs, tetralogy of Fallot, nasal bone anomaly and cleft palate. Following amniocentesis, G-band karyotyping and CMA were carried out. The fetus had a karyotype of 47,XX,+i(12)(p10) [14]/46,XX[6]. CMA has identified a 33.9 Mb duplication at 12p13.33-p11.1, which was suggestive of tetrasomy 12p. Combined chromosomal karyotyping and CMA can delineate the origin of abnormal chromosomal fragments during prenatal diagnosis. The fetus was diagnosed with Pallister-Killian syndrome.
- 10 July 2020
- Vol. 37 (7) , 771-773
[Prenatal diagnosis of a case of Pallister-Killian syndrome].
To carry out G-banded chromosomal karyotyping and chromosomal microarray analysis (CMA) for a fetus featuring multiple malformations. The fetus was found to have increased nuchal thickness, generalized edema, asymmetric lower limbs, tetralogy of Fallot, nasal bone anomaly and cleft palate. Following amniocentesis, G-band karyotyping and CMA were carried out. The fetus had a karyotype of 47,XX,+i(12)(p10) [14]/46,XX[6]. CMA has identified a 33.9 Mb duplication at 12p13.33-p11.1, which was suggestive of tetrasomy 12p. Combined chromosomal karyotyping and CMA can delineate the origin of abnormal chromosomal fragments during prenatal diagnosis. The fetus was diagnosed with Pallister-Killian syndrome.
- Open Access
- 22 November 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (1) , e1031
A new frameshift mutation in L1CAM producing X‐linked hydrocephalus
Background: X‐linked hydrocephalus (XLH), characterized by mental retardation and bilateral adducted thumbs, often come out to be a genetic disorder of L1CAM. It codes the protein L1 cell adhesion molecule (L1CAM), playing a crucial role in the development of the nervous system. The objective of the study was to report a new disease‐causing mutation site of L1CAM, and gain further insight into the pathophysiology of hydrocephalus.Methods: We collect the samples of a couple and their second hydrocephalic fetus. Then, the whole‐exome sequencing and in‐depth mutation analysis were performed.Results: The variant c.2491delG (p.V831fs), located in the exon 19 of L1CAM (chrX:153131214), could damage the L1CAM function by producing a frameshift in the translation of fibronectin type‐III of L1CAM.Conclusion: We identified a novel disease‐causing mutation in L1CAM for the first time, which further confirmed L1CAM as a gene underlying XLH cases.
- 22 November 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (1) , e1031
Open AccessA new frameshift mutation in L1CAM producing X‐linked hydrocephalus
Background: X‐linked hydrocephalus (XLH), characterized by mental retardation and bilateral adducted thumbs, often come out to be a genetic disorder of L1CAM. It codes the protein L1 cell adhesion molecule (L1CAM), playing a crucial role in the development of the nervous system. The objective of the study was to report a new disease‐causing mutation site of L1CAM, and gain further insight into the pathophysiology of hydrocephalus.Methods: We collect the samples of a couple and their second hydrocephalic fetus. Then, the whole‐exome sequencing and in‐depth mutation analysis were performed.Results: The variant c.2491delG (p.V831fs), located in the exon 19 of L1CAM (chrX:153131214), could damage the L1CAM function by producing a frameshift in the translation of fibronectin type‐III of L1CAM.Conclusion: We identified a novel disease‐causing mutation in L1CAM for the first time, which further confirmed L1CAM as a gene underlying XLH cases.